ADVISORY/Graphic depicting how TNKase(TM) acts in treating a heart attack is available on BW PhotoWire/AP PhotoExpress, NewsCom, PressLink and Business Wire's Web Site.Photo/Business Editors & Health/Medical Writers ADVISORY... --(BUSINESS WIRE) The photo is BW2 on AP PhotoExpress. The photo is on Business Wire's Web Site at URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. : http://www.businesswire.com/cgi-bin/photo.cgi?pw.060200/bw2 Photo caption reads: Genentech, Inc. (NYSE NYSE See: New York Stock Exchange :DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. ) announced today that TNKase(TM) (Tenecteplase), its new, single-bolus thrombolytic agent, which holds the potential to simplify heart attack treatment, has been approved by the U.S. Food and Drug Administration for the treatment of acute myocardial infarction acute myocardial infarction (  ·kyōōtˑ mī·ō·karˑ·dē· (AMI). TNKase is the first "clot-buster" that can be administered over five seconds in a single dose, offering physicians the fastest administration of a thrombolytic to date in the treatment of heart attack. (Business Wire photo) See BW 336 (CA-GENENTECH) that ran earlier today for more information. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion